The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized prospective trial evaluating duration of PD-1 and PD-L1 inhibitor therapy in advanced solid tumors.
 
Vincent Reyes
No Relationships to Disclose
 
Ryan Sweeney
No Relationships to Disclose
 
Mark Jelinek
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
Julie Alexander
Employment - Health Catalyst and ViaHealth Solutions (I)
Stock and Other Ownership Interests - Health Catalyst (I)
 
James Ohr
No Relationships to Disclose
 
Lijun Dai
No Relationships to Disclose
 
Gaurav Goel
Stock and Other Ownership Interests - United Health Group
Consulting or Advisory Role - IntegraConnect
 
Nitin Kapoor
No Relationships to Disclose
 
Christopher Marsh
No Relationships to Disclose
 
Daniel Petro
No Relationships to Disclose
 
Gauri Kiefer
No Relationships to Disclose
 
Dhaval Mehta
Stock and Other Ownership Interests - Abbvie; Lilly
Honoraria - Cardinal Health; Curio Science; IntegraConnect
Consulting or Advisory Role - AstraZeneca; BeiGene
Travel, Accommodations, Expenses - IntegraConnect
 
John Waas
Stock and Other Ownership Interests - Aurinia Pharmaceuticals; Biogen; Biohaven Pharmaceuticals; Bristol-Myers Squibb; Cardiff Oncology; Genmab; Madrigal Pharmaceuticals; Merck; Novo Nordisk; Verastem
 
Robert Ferris
Stock and Other Ownership Interests - Novasenta
Consulting or Advisory Role - Bicara Therapeutics; BMS; Bobcat Bio; Coherus Biosciences; CorriRX Therapeutics; CureVac; Fortvita Biologics, Inc; Johnson & Johnson; MeiraGTx; Merck; Merus NV; Mirror Biologics; Nanobiotix; Novasenta; Novotech; Pfizer; Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Merck (Inst); Merus NV
 
Rushir Choksi
Consulting or Advisory Role - IntegraConnect
Travel, Accommodations, Expenses - IntegraConnect
 
Stanley Marks
Employment - IntegraConnect (I)
 
Jason Luke
Stock and Other Ownership Interests - Actym Therapeutics; Kanaph Therapeutics; NeoTX; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - Abbvie; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Hotspot Therapeutics; Incyte; Merck; Novartis; Onc.AI; Pfizer; Regeneron; Tempest Therapeutics; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Ikena Oncology (Inst); Immatics (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Numab (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Merck
 
Antoinette Wozniak
Consulting or Advisory Role - Genentech
 
Dan Zandberg
Consulting or Advisory Role - Bicara Therapeutics; Blueprint Medicines; Coherus Biosciences; Coherus Biosciences; InhibRx; Macrogenics; Merck; Prelude Therapeutics; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); AVEO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)